BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Gukasyan N, Davis AK, Barrett FS, Cosimano MP, Sepeda ND, Johnson MW, Griffiths RR. Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. J Psychopharmacol 2022;36:151-8. [PMID: 35166158 DOI: 10.1177/02698811211073759] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
Number Citing Articles
1 Nikolaidis A, Lancelotta R, Gukasyan N, Griffiths RR, Barrett FS, Davis AK. Subtypes of the psychedelic experience have reproducible and predictable effects on depression and anxiety symptoms. J Affect Disord 2023;324:239-49. [PMID: 36584715 DOI: 10.1016/j.jad.2022.12.042] [Reference Citation Analysis]
2 Low F, Earleywine M. Educational Materials and Image Induction Increase Treatment Credibility. J Psychoactive Drugs 2023;:1-10. [PMID: 36682063 DOI: 10.1080/02791072.2022.2154722] [Reference Citation Analysis]
3 Pedicini M, Cordner ZA. Utility of preclinical models in the study of psilocybin - A comprehensive review. Neurosci Biobehav Rev 2023;146:105046. [PMID: 36646257 DOI: 10.1016/j.neubiorev.2023.105046] [Reference Citation Analysis]
4 Davoudian PA, Shao LX, Kwan AC. Shared and Distinct Brain Regions Targeted for Immediate Early Gene Expression by Ketamine and Psilocybin. ACS Chem Neurosci 2023. [PMID: 36630309 DOI: 10.1021/acschemneuro.2c00637] [Reference Citation Analysis]
5 Sayalı C, Barrett FS. The costs and benefits of psychedelics on cognition and mood. Neuron 2023:S0896-6273(22)01152-7. [PMID: 36681076 DOI: 10.1016/j.neuron.2022.12.031] [Reference Citation Analysis]
6 Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Int J Mol Sci 2023;24. [PMID: 36674849 DOI: 10.3390/ijms24021329] [Reference Citation Analysis]
7 Kelly JR, Clarke G, Harkin A, Corr SC, Galvin S, Pradeep V, Cryan JF, O'Keane V, Dinan TG. Seeking the Psilocybiome: Psychedelics meet the microbiota-gut-brain axis. Int J Clin Health Psychol 2023;23:100349. [PMID: 36605409 DOI: 10.1016/j.ijchp.2022.100349] [Reference Citation Analysis]
8 Morton E, Sakai K, Ashtari A, Pleet M, Michalak EE, Woolley J. Risks and benefits of psilocybin use in people with bipolar disorder: An international web-based survey on experiences of 'magic mushroom' consumption. J Psychopharmacol 2023;37:49-60. [PMID: 36515370 DOI: 10.1177/02698811221131997] [Reference Citation Analysis]
9 Greener M. New antidepressants: monoamines and beyond. Prescriber 2023;34:17-20. [DOI: 10.1002/psb.2032] [Reference Citation Analysis]
10 Meccia J, Lopez J, Bagot RC. Probing the antidepressant potential of psilocybin: integrating insight from human research and animal models towards an understanding of neural circuit mechanisms. Psychopharmacology (Berl) 2023;240:27-40. [PMID: 36564671 DOI: 10.1007/s00213-022-06297-0] [Reference Citation Analysis]
11 Modlin NL, Miller TM, Rucker JJ, Kirlic N, Lennard-jones M, Schlosser D, Aaronson ST. Optimizing outcomes in psilocybin therapy: Considerations in participant evaluation and preparation. Journal of Affective Disorders 2023. [DOI: 10.1016/j.jad.2023.01.077] [Reference Citation Analysis]
12 von Rotz R, Schindowski EM, Jungwirth J, Schuldt A, Rieser NM, Zahoranszky K, Seifritz E, Nowak A, Nowak P, Jäncke L, Preller KH, Vollenweider FX. Single-dose psilocybin-assisted therapy in major depressive disorder: A placebo-controlled, double-blind, randomised clinical trial. EClinicalMedicine 2023;56:101809. [PMID: 36636296 DOI: 10.1016/j.eclinm.2022.101809] [Reference Citation Analysis]
13 Bradshaw AJ, Backman TA, Ramírez-Cruz V, Forrister DL, Winter JM, Guzmán-Dávalos L, Furci G, Stamets P, Dentinger BTM. DNA Authentication and Chemical Analysis of Psilocybe Mushrooms Reveal Widespread Misdeterminations in Fungaria and Inconsistencies in Metabolites. Appl Environ Microbiol 2022;88:e0149822. [PMID: 36445079 DOI: 10.1128/aem.01498-22] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Schindler EAD, D'Souza DC. The therapeutic potential of psychedelics. Science 2022;378:1051-3. [PMID: 36480624 DOI: 10.1126/science.abn5486] [Reference Citation Analysis]
15 Kelly DF, Heinzerling K, Sharma A, Gowrinathan S, Sergi K, Mallari RJ. Psychedelic-Assisted Therapy and Psychedelic Science: A Review and Perspective on Opportunities in Neurosurgery and Neuro-Oncology. Neurosurgery 2022;Publish Ahead of Print. [DOI: 10.1227/neu.0000000000002275] [Reference Citation Analysis]
16 Marseille E, Bertozzi S, Kahn JG. The economics of psychedelic-assisted therapies: A research agenda. Front Psychiatry 2022;13:1025726. [PMID: 36545038 DOI: 10.3389/fpsyt.2022.1025726] [Reference Citation Analysis]
17 Passie T, Guss J, Krähenmann R. Lower-dose psycholytic therapy – A neglected approach. Front Psychiatry 2022;13. [DOI: 10.3389/fpsyt.2022.1020505] [Reference Citation Analysis]
18 Gukasyan N, Schreyer CC, Griffiths RR, Guarda AS. Psychedelic-Assisted Therapy for People with Eating Disorders. Curr Psychiatry Rep 2022;24:767-75. [PMID: 36374357 DOI: 10.1007/s11920-022-01394-5] [Reference Citation Analysis]
19 Turkia M. Self-treatment of psychosis and complex post-traumatic stress disorder with LSD and DMT—A retrospective case study. Psychiatry Research Case Reports 2022;1:100029. [DOI: 10.1016/j.psycr.2022.100029] [Reference Citation Analysis]
20 Madras BK. Psilocybin in Treatment-Resistant Depression. N Engl J Med 2022;387:1708-1709. [DOI: 10.1056/nejme2210975] [Reference Citation Analysis]
21 Outhoff K. The magic of psychedelics – a tale told in quotation marks. South African General Practitioner 2022;3:141-143. [DOI: 10.36303/sagp.2022.3.5.0150] [Reference Citation Analysis]
22 Ledwos N, Rosenblat JD, Blumberger DM, Castle DJ, McIntyre RS, Mulsant BH, Husain MI. A Critical Appraisal of Evidence on the Efficacy and Safety of Serotonergic Psychedelic Drugs as Emerging Antidepressants: Mind the Evidence Gap. J Clin Psychopharmacol 2022. [PMID: 36193898 DOI: 10.1097/JCP.0000000000001608] [Reference Citation Analysis]
23 Pilc A, Machaczka A, Kawalec P, Smith JL, Witkin JM. Where do we go next in antidepressant drug discovery? A new generation of antidepressants: a pivotal role of AMPA receptor potentiation and mGlu2/3 receptor antagonism. Expert Opin Drug Discov 2022;17:1131-46. [PMID: 35934973 DOI: 10.1080/17460441.2022.2111415] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Ko K, Kopra EI, Cleare AJ, Rucker JJ. TEMPORARY REMOVAL: Psychedelic therapy for depressive symptoms: Asystematic review and meta-analysis. Journal of Affective Disorders 2022. [DOI: 10.1016/j.jad.2022.09.168] [Reference Citation Analysis]
25 Barba T, Buehler S, Kettner H, Radu C, Cunha BG, Nutt DJ, Erritzoe D, Roseman L, Carhart-Harris R. Effects of psilocybin versus escitalopram on rumination and thought suppression in depression. BJPsych Open 2022;8:e163. [PMID: 36065128 DOI: 10.1192/bjo.2022.565] [Reference Citation Analysis]
26 Eisenstein M. The psychedelic escape from depression. Nature 2022;609:S87-9. [PMID: 36171370 DOI: 10.1038/d41586-022-02872-9] [Reference Citation Analysis]
27 Barnett BS, Weleff J. Psychedelics in the Treatment of Substance Use Disorders. Psychiatric Annals 2022;52:365-70. [DOI: 10.3928/00485713-20220804-01] [Reference Citation Analysis]
28 Rosenblat JD, Husain MI, Lee Y, McIntyre RS, Mansur RB, Castle D, Offman H, Parikh SV, Frey BN, Schaffer A, Greenwaym KT, Garel N, Beaulieu S, Kennedy SH, Lam RW, Milev R, Ravindran AV, Tourjman V, Ameringen MV, Yatham LN, Taylor V. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder. Can J Psychiatry 2022;:7067437221111371. [PMID: 35975555 DOI: 10.1177/07067437221111371] [Reference Citation Analysis]
29 Prouzeau D, Conejero I, Voyvodic PL, Becamel C, Abbar M, Lopez-Castroman J. Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review. Curr Psychiatry Rep 2022. [PMID: 35953638 DOI: 10.1007/s11920-022-01361-0] [Reference Citation Analysis]
30 Levin A, Nagib PB, Deiparine S, Gao T, Mitchell J, Davis AK. Inconsistencies between national drug policy and professional beliefs about psychoactive drugs among psychiatrists in the United States. Int J Drug Policy 2022;108:103816. [PMID: 35964449 DOI: 10.1016/j.drugpo.2022.103816] [Reference Citation Analysis]
31 Mccartney AM, Mcgovern HT, De Foe A. Psychedelic assisted therapy for major depressive disorder: Recent work and clinical directions. JPS 2022. [DOI: 10.1556/2054.2022.00211] [Reference Citation Analysis]
32 Sotille R, Singh H, Weisman A, Vida T. Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus 2022;14:e25414. [PMID: 35769681 DOI: 10.7759/cureus.25414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
33 Cole-turner R. Psychedelic Mystical Experience: A New Agenda for Theology. Religions 2022;13:385. [DOI: 10.3390/rel13050385] [Reference Citation Analysis]
34 van den Berg M, Magaraggia I, Schreiber R, Hillhouse TM, Porter JH. How to account for hallucinations in the interpretation of the antidepressant effects of psychedelics: a translational framework. Psychopharmacology (Berl) 2022. [PMID: 35348806 DOI: 10.1007/s00213-022-06106-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Davoudian PA, Shao L, Kwan AC. Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin.. [DOI: 10.1101/2022.03.18.484437] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]